Document Detail

Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.
MedLine Citation:
PMID:  17135223     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) trial has recently reported.
OBJECTIVE: To assess the cost effectiveness of perindopril in stable coronary heart disease in the UK.
METHODS: Clinical and resource use data were taken from the EUROPA trial. Costs included drugs and hospitalisations. Health-related quality of life values were taken from published sources. A cost-effectiveness analysis is presented as a function of the risk of a primary event (non-fatal myocardial infarction, cardiac arrest or cardiovascular death) in order to identify people for whom treatment offers greatest value for money.
RESULTS: The median incremental cost of perindopril for each quality-adjusted life year (QALY) gained across the heterogeneous population of EUROPA was estimated as 9700 pounds(interquartile range 6400-14,200 pounds). Overall, 88% of the EUROPA population had an estimated cost per QALY below 20,000 pounds and 97% below 30,000 pounds. For a threshold value of cost effectiveness of 30,000 pounds per QALY gained, treatment of people representing the 25th, 50th (median) and 75th centiles of the cost effectiveness distribution for perindopril has a probability of 0.999, 0.99 and 0.93 of being cost effective, respectively. Cost effectiveness was strongly related to higher risk of a primary event under standard care.
CONCLUSIONS: Whether the use of perindopril can be considered cost effective depends on the threshold value of cost effectiveness of healthcare systems. For the large majority of patients included in EUROPA, the incremental cost per QALY gained was lower than the apparent threshold used by the National Institute for Health and Clinical Excellence in the UK.
Andrew Briggs; Borislava Mihaylova; Mark Sculpher; Alistair Hall; Jane Wolstenholme; Maarten Simoons; Jaap Deckers; Roberto Ferrari; Willem J Remme; Michel Bertrand; Kim Fox;
Related Documents :
868753 - Risk-benefit analysis for industrial and social needs.
9115483 - Ambulatory surgery. an evolution.
25423853 - Perceptions and use of maternal health services by women in rural coastal madang province.
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2006-11-29
Journal Detail:
Title:  Heart (British Cardiac Society)     Volume:  93     ISSN:  1468-201X     ISO Abbreviation:  Heart     Publication Date:  2007 Sep 
Date Detail:
Created Date:  2007-08-16     Completed Date:  2007-10-04     Revised Date:  2013-06-07    
Medline Journal Info:
Nlm Unique ID:  9602087     Medline TA:  Heart     Country:  England    
Other Details:
Languages:  eng     Pagination:  1081-6     Citation Subset:  AIM; IM    
Public Health and Health Policy, University of Glasgow, Glasgow, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin-Converting Enzyme Inhibitors / economics,  therapeutic use*
Cardiovascular Agents / economics,  therapeutic use
Cardiovascular Diseases / economics,  prevention & control*
Coronary Disease / drug therapy
Cost-Benefit Analysis
Drug Costs / statistics & numerical data
Health Care Costs / statistics & numerical data*
Hospitalization / statistics & numerical data
Length of Stay / statistics & numerical data
Middle Aged
Perindopril / economics,  therapeutic use*
Quality-Adjusted Life Years
Risk Assessment / methods
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Cardiovascular Agents; 82834-16-0/Perindopril
Comment In:
Heart. 2007 Sep;93(9):1015-6   [PMID:  17699166 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of blood pressure on the Doppler echocardiographic assessment of severity of aortic stenosis.
Next Document:  Left ventricular non-compaction cardiomyopathy in children: characterisation of clinical status usin...